In a MM cell line study, bromodomain extra-terminal (BET) protein inhibitors were synergized with proteasome inhibitors (carfilzomib, CFZ) to accelerate proteotoxic stress-mediated cell death in vitro, by inhibiting the NFE2L1-mediated “bounce-back” effect [120]. This evidence concerns the gene NFE2L1 and Miyoshi myopathy.